Polaris Venture Management Co V’s Cartesian Therapeutics RNAC Stock Holding History

Polaris Venture Management Co V’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-92,449	Closed	-$12.6M	–	8
2021 Q1	$12.6M	Hold	92,449	–	–	16.27%	3
2020 Q4	$8.4M	Hold	92,449	–	–	10.97%	3
2020 Q3	$6.88M	Hold	92,449	–	–	11.34%	3
2020 Q2	$7.88M	Hold	92,449	–	–	6.13%	4
2020 Q1	$6.68M	Hold	92,449	–	–	6.05%	3
2019 Q4	$6.65M	Hold	92,449	–	–	4.84%	4
2019 Q3	$4.85M	Hold	92,449	–	–	2.76%	5
2019 Q2	$4.96M	Hold	92,449	–	–	3.9%	5
2019 Q1	$6.57M	Buy	92,449 +38,889	+73%	+$2.46M	5.56%	5
2018 Q4	$4.27M	Hold	53,560	–	–	4.56%	7
2018 Q3	$25M	Hold	53,560	–	–	12.51%	4
2018 Q2	$21.3M	Hold	53,560	–	–	11.6%	5
2018 Q1	$16.4M	Hold	53,560	–	–	9.33%	5
2017 Q4	$15.8M	Sell	53,560 -691	-1%	-$302K	13.9%	3
2017 Q3	$29.7M	Sell	54,251 -9,887	-15%	-$5.26M	25.53%	2
2017 Q2	$38.2M	Hold	64,138	–	–	39.54%	1
2017 Q1	$27.6M	Hold	64,138	–	–	29.5%	1
2016 Q4	$33M	Hold	64,138	–	–	39.17%	1
2016 Q3	$27.4M	Hold	64,138	–	–	28.95%	1
2016 Q2	$26.9M	Buy	+64,138	New	+$26.9M	28.9%	1

Other funds holding RNAC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Polaris Venture Management Co V's RNAC Position: Q2 2021 in Review

Polaris Venture Management Co V sold out of Cartesian Therapeutics (RNAC) in Q2 2021, closing a stake of 92,449 shares — an estimated $12.6M sold.

Polaris Venture Management Co V first reported a position in RNAC in Q2 2016 and held it in 20 quarters. The position peaked at $38.2M in Q2 2017. 101 funds tracked by Wall St. Rank hold RNAC as of Q2 2021.

Polaris Venture Management Co V reported no remaining Cartesian Therapeutics position as of Q2 2021 after selling out during the quarter.
Polaris Venture Management Co V sold 92,449 Cartesian Therapeutics shares in Q2 2021, an estimated $12.6M.
Polaris Venture Management Co V first reported a position in Cartesian Therapeutics in Q2 2016 and held it in 20 quarters.
Polaris Venture Management Co V's Cartesian Therapeutics position peaked at $38.2M in Q2 2017.
101 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2021.

Based on Polaris Venture Management Co V's 13F filing for Q2 2021, filed 12 Aug 2021.